I
T IS WELL established that vitamin D3 (VD3) acts as a modulator of cell growth, differentiation, maintenance of extracellular calcium levels, bone mineralization, and lipid metabolism. VD3 exerts its actions through nuclear VD3 receptor (VDR)-mediated signal transduction and gene transcription (1) . Another well-established nuclear receptor subfamily, peroxisome proliferator-activated receptors (PPARs), comprising PPAR␣, -␦ (␤), and -␥, binds fatty acids and play important roles in energy homeostasis. Thiazolidine derivatives, such as troglitazone and pioglitazone, which are selective PPAR␥ agonists, reduce hyperlipidemia in obese and diabetic animals (2) (3) (4) (5) . VDR and/or PPARs regulate gene transcription to modulate uptake of calcium, phosphate, lipids, and glucose from plasma (6, 7) . In addition, several reports have suggested that VDR and PPARs have a regulatory role in the uptake of plasma proteins (8 -11) . However, the regulatory role and mechanisms of the membrane-associated function of VDR and PPARs largely remains to be clarified.
In the course of our study of thioredoxin (TRX), an important redox regulator (12, 13) , we identified TRX-binding protein (TBP)-2 (14) , which is identical with VD3 up-regulated protein 1 (VDUP1), a VD3-inducible gene in HL-60 cells (15) . Several reports show that loss of TBP-2 expression is associated with cell growth or transformation. TBP-2 is down-regulated in human T cell leukemia virus I-transformed cells and human cancer tissues (16 -19) , whereas overexpression of TBP-2 induces cell growth suppression (18 -20) . Interestingly, HcB-19 mice, which have a nonsense mutation in the TBP-2 gene, exhibit hyperlipidemia characterized by elevated plasma triglyceride and/or cholesterol levels (21) . The analyses of the HcB-19 mice (22) or TBP-2 knockout mice (23) revealed that TBP-2 plays a critical role in the integrated regulation of glucose and lipid metabolism in fasting. The molecular mechanisms underlying transformation and hyperlipidemia caused by loss of TBP-2 function remain to be elucidated, as does the mechanism behind the physiological function of TBP-2.
In this paper, we report that there are three homologous TBP-2/VDUP1 genes in humans. The TBP-2 homologs constitute a family and are preserved in Schizosaccharomyces pombe, Saccharomyces cerevisiae, Drosophila melanogaster, and Caenorhabditis elegans but not Escherichia coli, indicating that the genes have evolutionarily conserved roles in the eukaryotic system. However, the functions of these family members have not been clarified. Characterization of members of the human TBP-2 family will provide new insights into the biological roles of these genes. We have cloned a human TBP-2 homolog, TBP-2-like inducible membrane protein (TLIMP), and show that TLIMP and TBP-2 are VD3/PPAR␥ ligandinducible genes. To investigate the biological role of the TBP-2 gene family and understand the molecular mechanism of the VD3/PPAR-mediated cellular function, we characterized TLIMP and investigated the role of TLIMP in cellular growth regulation and PPAR␥ ligand-induced gene activation. 
Materials and Methods

Reagents and materials
Amino acid sequence alignment
Amino acid sequences of TBP-2 family proteins were aligned using the ClustalW program (EMBL-European Bioinformatics Institute) and the BOXSHADE program (Swiss Institute of Bioinformatics) was used for formatting the results.
Plasmids
The open reading frame of TLIMP was amplified by PCR using the oligonucleotide primers 5Ј-AATGGATCCATGGTGCTGGGAAAGGT-GAA-3Ј and 5Ј-CGAATTCAACGAGAGGGGCAGGAT-3Ј. The cDNAs were subcloned into pCMV-Tag2B (CLONTECH) and pGEX6P1 (Amersham Biosciences, Piscataway, NJ) to generate pCMV-Flag-TLIMP and pGST-TLIMP, respectively. pEF-BSR, a blasticidin-resistant mammalian expression vector driven by the elongation factor (EF) 1 promoter, was kindly provided by Dr. Ishii (Riken Research Center for Allergy and Immunology, Yokohama, Japan). The cDNA containing a Kozak sequence in the 5Ј side of the TLIMP gene lacking a stop codon was obtained by PCR using oligonucleotide primers 5Ј-GGAATTCGCCAC-CATGGTGCTGGGAAAGGT-3Ј and 5Ј-CGGGATCCACGAGAGG-GGCAGGATGGTCTA-3Ј. The TLIMP cDNA was ligated into pEF-BSR downstream of the EF promoter, and then a DNA fragment encoding the Flag epitope or enhanced green fluorescent protein (EGFP; pEGFP-N3; CLONTECH) was inserted into the 3Ј end of TLIMP to generate pEF-BSR-TLIMP-Flag or pEF-BSR-TLIMP-EGFP, respectively. The N-terminal Flag epitope-tagged TBP-2 cDNA was ligated into pEF-BSR to generate pEF-BSR-Flag-TBP-2. Yeast expression vectors, pGBKT7-TLIMP and pGBKT7-TBP-2, for the expression of TLIMP or TBP-2 fused with the GAL4 DNA-binding domain were constructed by insertion of the open reading frames of TLIMP and TBP-2 into pGBKT7 (CLONTECH). The cDNA of TRX was ligated into pACT2 (CLONTECH) to generate pACT2-TRX, an expression vector for the GAL4 activation domain fused with TRX. Luciferase reporter plasmids containing five GAL4 binding sites in the promoter region (pGAL4-luc), and plasmid expressing PPAR␥2 fused to the GAL4 DNA binding domain (pM-PPAR␥2) and HA-tag (pcDNA3-HA-PPAR␥2) were kindly provided by Dr. Ohshima (24) .
Cell culture and transfection
HL-60 cells were cultured in RPMI 1640 medium. HeLa S3, COS7, and 293 cells were cultured in DMEM. CHO cells were cultured in F-12 medium. Heat-inactivated fetal calf serum (FCS) and antibiotics were added to the media. Cells were transfected with Lipofectamine (Invitrogen, Carlsbad, CA), according to the manufacturer's instructions. Stable transfectants were generated by transfection of HeLa S3 cells with either pEF-BSR-TLIMP-Flag or pEF-BSR control plasmid. After 24 h, cells were plated and selected in medium containing 4 g/ml blasticidin. The expression of TLIMP in the transfectants was confirmed by Western blotting analyses. Reporter assay were performed as described previously (25) . NIH3T3 cells were transfected with the TLIMP and GAL4-PPAR␥2 expression vectors and luciferase reporter plasmids containing five GAL4 binding sites in the promoter region. Cells were then treated with troglitazone and luciferase reporter assay were performed (24) .
Northern blotting analysis
Total RNA from cells was extracted using TRIzol reagent (Invitrogen), according to the manufacturer's instructions. Total RNA (10 -20 g/lane) was fractionated by denaturing agarose gel electrophoresis and transferred to a nylon membrane (Hybond N ϩ ; Amersham Biosciences). The blots were hybridized with a [
32 P]-labeled probe prepared using the BcaBest labeling kit (Takara, Shiga, Japan) overnight at 68 C.
Semiquantitative RT-PCR
Total RNAs from cells and tissues were extracted using TRIzol reagent (Invitrogen), according to the manufacturer's instructions. Reverse transcription was performed with a SuperScript III first-strand synthesis system kit (Invitrogen). PCRs were carried out using the following oligonucleotide primers: human TLIMP forward primer, 5Ј-ATGGTGCTGGGAAAGGTGAA-3Ј, and reverse primer, 5Ј-TCAA-CGAGAGGGGCAGGAT-3Ј; human TBP-2 forward primer, 5Ј-AAGG-TGCTGACTCAGAAG-3Ј, and reverse primer, 5Ј-CTCACTGCACATT-GTTGTTG-3Ј; human glyceraldehyde-3-phosphate dehydrogenase forward primer, 5Ј-ATGGGGAAGGTGAAGGTCGGAGTC-3Ј, and reverse primer, 5Ј-CCATGCCAGTGAGCTTCCCGTTC-3Ј; mouse TLIMP forward primer, 5Ј-ACAGTTACAGTGCCTGAGAAGACTCGG-3Ј, and reverse primer, 5Ј-GTGCCCTCAGGTGTTACGTCAAG-3Ј; mouse TBP-2 forward primer, 5Ј-GTGATGGATCTAGTGGATGTC-3Ј, and reverse primer, 5Ј-TCACTGCACGTTGTTGTTG-3Ј; mouse fatty acidbinding protein 4 (FABP4) forward primer, 5Ј-ACAAAATGTGTGAT-GCCTTTGTGGGAAC-3Ј, and reverse primer, 5Ј-TCCGACTGACTAT-TGTAGTGTTTGATGCAA-3Ј; mouse lipoprotein lipase (LPL) forward primer, 5Ј-GGGGTACCTGCCCACCACTTGTCCCCTGGAG-3Ј, and reverse primer, 5Ј-CGGGATCCCGGTGCACCCTTCTGCTTTGCTGC-3Ј; and mouse ␤-actin forward primer, 5Ј-ATGGATGACGATATCGC-TGCGCT-3Ј, and reverse primer, 5Ј-TAGAAGCACTTGCGGTGCACG-AT-3Ј. Amplification of the products is not saturated with the number of cycles performed.
Western blotting analysis
Cell lysates or immunoprecipitates were fractionated by SDS-PAGE and then transferred to a polyvinylidene difluoride membrane (Amersham Biosciences). Western blot analysis was performed using an enhanced chemiluminescence Western blotting detection system (Amersham Biosciences), according to the manufacturer's instructions.
Subcellular fractionation
Cells (at confluence in a 3.5 cm dish) were lysed with lysis buffer [25 mm Tris-HCl (pH 7.8), 2 mm dithiothreitol (DTT), 10% glycerol, 1% Trition X-100, and 1ϫ complete protease inhibitor cocktail] and the cell lysate was centrifuged at 100,000 ϫ g for 10 min. The supernatant, the Triton X-100 soluble fraction (100 l) was transferred to a new tube, and 25 l of 5ϫ sample buffer [500 mm Tris-HCl (pH 6.8), 10% sodium dodecyl sulfate, 25% glycerol, 12.5% 2-mercaptoethanol, and 0.25% bromophenol blue] was added. The pellet, the Triton X-100 insoluble fraction, was resuspended with 125 l of 1ϫ sample buffer (5-fold dilution of 5ϫ sample buffer with lysis buffer) before sonication. The fractionated samples were subjected to Western blotting analyses.
Immunofluorescent staining
Cells were cultured on glass-bottom dishes, fixed with 4% paraformaldehyde in PBS for 5 min at room temperature, and permeabilized for 5 min using 1% Nonidet P-40 in PBS. The permeabilized cells were incubated in PBS containing 1.5% FCS and then with anti-Flag antibody (Sigma) or anti-Myc antibody (Santa Cruz Biotechnology, Santa Cruz, CA), followed by FITC-or Alexa 568-conjugated antimouse IgG. The immunostained cells were examined with a confocal microscope (Leica Microsystems, Mannheim, Germany).
Preparation of recombinant proteins and in vitro binding assay
In vitro-translated proteins were prepared using a TNT-coupled rabbit reticulocyte translation system (Promega, Madison, WI). The [
35 S]methionine-labeled translated products were analyzed by SDS-PAGE after performance of a glutathione-S-transferase (GST) pull-down assay. GST-TRX was prepared as described previously (14) . The precipitates were detected by autoradiography using a Bio-image analyzer BAS2000 (Fuji Film Co. Ltd., Tokyo, Japan) or Coomassie Brilliant Blue staining. 
Insulin-reducing assay
Yeast two-hybrid analysis
The yeast two-hybrid analysis was performed using the yeast MATCHMAKER two-hybrid system (CLONTECH), according to the manufacturer's directions. S. cerevisiae strain AH109 transformed with pGBKT7-TLIMP or pGBKT7-TBP-2, together with either pACT2 or pACT2-TRX, respectively. Transformed colonies were cultured in synthetic medium with or without histidine.
Cell proliferation assay
Blasticidin-resistant mammalian expression vectors were introduced into CHO cells, and the cells were cultured with 8 g/ml of blasticidincontaining medium for 2 or 3 d to eliminate the nonresistant cells. The blasticidin-resistant cells (3-5 ϫ 10 3 cells in 100 l of culture medium containing 8 g/ml of blasticidin) were cultured in 96-well flat-bottom microtiter plates. Cell proliferation was measured as the formation of formazan using SF cell-counting reagents (Nacalai Tesque, Kyoto, Japan), according to the manufacturer's instructions.
Colony formation assay
Blasticidin-resistant mammalian expression vectors were introduced into HeLa S3 cells, and the cells were cultured with 4 g/ml of blasticidin-containing medium for 3 d. The cells (1 ϫ 10 6 cells) were plated in 0.35% agar containing DMEM, 10% FCS, and 4 g/ml of blasticidin on a 0.5% agar base layer containing DMEM. The total number of foci was scored after 10 d.
Statistical methods
Results are expressed as means Ϯ sd. Statistical comparisons were made using Student's t test or ANOVA coupled with a Fisher's test. A statistically significant difference was defined as P Ͻ 0.05, which is represented by an asterisk in the data presentation.
Results
TBP-2 protein family
As shown in Fig. 1A , BLAST searches were used to identify human genes homologous to TBP-2. DRH1 and two other genes (GenBank accession no. AF193051 and BC015928) were identified. DRH1 has been reported as a gene that is downregulated in advanced human hepatocellular carcinoma (26) . Here we refer to BC015928 as TLIMP, which was originally identified as KIAA1376 when it was found in the full-length human cDNA sequencing project (27) . The function of AF193051 has not been reported. TLIMP has 40% identity and over 80% similarity with TBP-2 at the amino acid level, and the other genes also exhibit high levels of identity and similarity. All the genes included eight exons, each of which encodes a corresponding region of the protein (Fig. 1B and  supplemental Fig. 1 , published as supplemental data on The Endocrine Society's Journals Online web site at http:/ / endo.endojournals.org). Therefore, it is likely that this mammalian gene family was generated by gene duplications. The members of the TBP-2 gene family also have some homology to arrestin proteins. For example, TLIMP has 25% similarity with ␤-arrestin-1 at the amino acid level. TBP-2 and arrestins have similar numbers of amino acids (ϳ400) and show overall similarity, rather than just a highly conserved region.
TLIMP cDNA was cloned from a 293-cell cDNA library by PCR and then sequenced. Two isoforms of TLIMP cDNA with different lengths were found (Fig. 1C) . The longer cDNA encoded full-length TLIMP, producing a protein of 414 amino acids. The shorter TLIMP splice variant, referred to as TLIMPs, lacks 148 bp corresponding to exon 3, generating a 24-amino-acid C-terminal tail and a translational stop codon and producing a shorter protein of 144 amino acids (Fig. 1D) .
Tissue distribution of TLIMP expression
The expression of TLIMP was analyzed in normal human tissues and human cancer cell lines, and as shown in Fig. 2A , the size of TLIMP mRNA was about 4.5 kb in both normal and cancer cells. Strong expression of TLIMP was detected in normal skeletal muscle, placenta, kidney, adrenal gland, lymph node, mammary gland, thyroid, and trachea, but only very weak expression was detected in normal colon, thymus, spleen, small intestine, bladder, and bone marrow. In human cancer cell lines, TLIMP was strongly expressed in the lung adenocarcinoma cell line A549, whereas low expression levels were observed in other cancer cell lines. The expression of TBP-2 was strong in normal heart, skeletal muscle, spleen, and peripheral blood lymphocytes, and weak in normal brain and liver (Fig. 2B) . The distribution of TLIMP was clearly different from that of TBP-2 in some tissues.
TLIMP does not interact with TRX
TBP-2 binds to TRX in vivo and in vitro (14) , but no interaction of TLIMP with TRX was detected in a yeast two-hybrid analysis, as shown in Fig. 3A . The same analysis showed binding of TRX with TBP-2. Similar results were obtained in in vitro binding assays, in which TBP-2 coprecipitated with GST-TRX, but TLIMP failed to do so (Fig. 3B) . Overexpres-sion of TBP-2 has been shown to suppress the reducing activity of TRX (14) , and the effect of TLIMP on this activity was examined in an insulin-reducing assay. TRX-reducing activity was not significantly changed in cellular extracts transiently expressing TLIMP, whereas it was significantly suppressed in cellular extracts transfected with TBP-2 (Fig.  3C) . These results indicate that TRX interacts with TBP-2 but not with TLIMP.
Intracellular localization of TLIMP
To determine the intracellular distribution of TLIMP, Flagtagged TLIMP (TLIMP-Flag) was expressed in HeLa S3, 293, COS7, and CHO cells. The cellular distribution of TLIMPFlag is shown in Fig. 4A . Immunofluorescent analysis using anti-Flag antibody showed that TLIMP is present in the plasma membrane and small vesicular structures scattered throughout the cytoplasm. As reported previously, TBP-2 was detected mainly in the nucleus and partly in the cytoplasm in COS7 cells (19) . To determine whether TLIMP is expressed on the inner or outer side of the plasma membrane, TLIMP-Flag was expressed in HeLa S3 cells and stained by Nonidet P-40 without permeabilization. TLIMP-Flag was not stained in the nonpermeabilized cells but significantly stained in the permeabilized cells, indicating that TLIMP is expressed on the inner side of the plasma membrane (Fig. 4B) . The vesicular pattern of TLIMP protein expression in cytoplasm is similar to that of endosomes or lysosomes. To analyze whether TLIMP is present in the cellular compartments, we examined the distribution of EGFP-tagged TLIMP with Alexa633-conjugated transferrin and LysoTracker Blue, which are markers for endosomes and lysosomes, respectively. As shown in Fig.  4C , TLIMP-EGFP showed a similar distribution to TLIMPFlag, and the fluorescence merged with that of transferrin or LysoTracker in intracellular vesicular structures. Merging of all three fluorescent signals was observed in several areas. Whereas internalized transferrin is predominantly recycled to the plasma membrane through recycling of endosomes, low-density lipoprotein (LDL) is internalized and transported into lysosomes. To validate whether TLIMP is present in the lysosomal pathway, the cellular localizations of TLIMP and LDL were examined. As shown in Fig. 4D , the fluorescence of internalized LDL partly merged with TLIMP. These results suggest that TLIMP expression is associated with the plasma membrane, endosomes, and lysosomes during endocytosis. 
FIG. 2. Analysis of TLIMP expression: tissue distribution of TLIMP (A) and TBP-2 (B)
. RNA blots containing poly (A)ϩ RNA from multiple human tissues or cancer cell lines were hybridized with full-length TLIMP or TBP-2 cDNA as a probe. Human ␤-actin was used as a control to determine the relative amount of RNA from each of the tissues or cells.
Regulation of TLIMP expression
Because TBP-2 was first identified as a gene, the expression of which was induced by VD3 in HL-60 cells, TLIMP expression in VD3-treated HL-60 cells was examined. Expression of TLIMP was also induced when HL-60 cells were cultured in the presence of VD3, in a time-and dose-dependent manner (Fig. 5A) . The effects of retinoic acid (RA) and PMA on the expression of TBP-2 and TLIMP were then tested. RA and PMA are known to induce differentiation of HL-60 cells into granulocytes and macrophage-like cells, respectively. As shown in Fig. 5B , specific morphological changes in HL-60 cells were observed on treatment with RA, VD3, and PMA. RA did not induce TBP-2 or TLIMP expression, whereas PMA significantly induced the expression of TLIMP but not TBP-2. The extent of induction of TLIMP expression by PMA was less than that by VD3. TRX expression decreased in cells treated with VD3, RA, and PMA.
PPAR␥ has been implicated in the regulation of cell growth and differentiation of cells or tissues, such as adipose tissues, breast, and colon (28) . Similarly to VD3, PPAR ligands induce monocytic differentiation and concomitantly inhibit cell proliferation in HL-60 cells (29, 30) . These findings led us to hypothesize that members of the TBP-2 family have a role in the biological responses elicited by not only VD3 but also PPAR ligands. Therefore, the effects of PPAR ligands on the expression of TBP-2 and TLIMP were examined in HL-60 cells. Troglitazone, a selective PPAR␥ agonist, significantly induced both TBP-2 and TLIMP expression in a time-and dose-dependent manner (Fig. 5C ). These genes were also up-regulated by pioglitazone, another PPAR␥ agonist. Clofibrate, a selective PPAR␣ agonist, markedly induced TBP-2 expression but had no effect on TLIMP expression. These results suggest that TBP-2 and TLIMP are both up-regulated by PPAR␥ ligands but differentially regulated by PPAR␣ ligands. TRX expression was decreased with all the PPAR agonists tested, showing a reciprocal pattern to TBP-2 expression (Fig. 5D ). To further study the effect of PPAR ligands on the expression of these genes, we examined the effects of L165,041, a PPAR␤/␦ ligand, and prostaglandin J2, an endogenous ligand of PPAR␥, on the levels of TLIMP and TBP-2 expression (31). As shown in Fig. 5E , both TLIMP and TBP-2 are up-regulated by prostaglandin J2 but not L165,041. Collectively, the above results indicate that both TLIMP and TBP-2 are downstream regulatory proteins of VD3 and PPAR␥.
Because PPAR␥ plays an important role in differentiation in adipocytes as well as monocytes, the expression levels of TLIMP and TBP-2 were examined during differentiation of adipocytes in vitro. As shown in Fig. 6 , both TLIMP and TBP-2 are strongly expressed in adipocytes, compared with preadipocytes, indicating that these genes are up-regulated in association with differentiation of adipocytes. Expression of TLIMP and TBP-2 was also detected in brown and white adipose tissues in vivo (Fig. 6B) , and collectively these results suggest that both TLIMP and TBP-2 play a role in the differentiation and function of adipocytes. 35 S-labeled TLIMP or TBP-2 precipitated with GST-TRX or GST immobilized on GSH beads. The right panel shows that equal amounts of GST-fusion proteins were used in the pull-down assay, as determined by Coomassie Brilliant Blue staining. C, The effect of TRX activity on TLIMP expression. The TRX activity of the extract of COS7 cells transiently transfected with the indicated amount of expression vector for GFP-TBP-2 or GFP-TLIMP fusion proteins was determined in an insulin reducing assay. Expression vectors (10 g/plate) were introduced into cells cultured in 10-cm dishes. The total DNA concentration was kept constant using pEGFP-C1. Activities of samples are shown relative to the control value (lane 1), which is taken as 100%. The results are shown as the mean Ϯ SD of three samples.
Suppression of cell growth by TLIMP
VD3 and PPAR ligands are known to have strong cell growth-inhibitory activity in HL-60 cells, and previous reports have shown that TBP-2 also inhibits cell proliferation (18, 19) . To investigate whether TLIMP also has this inhibitory activity, the effect of overexpression of TLIMP on cell proliferation was examined. In TLIMP transfectants, TLIMP was mainly detected in the Triton X-100-insoluble fraction (Fig. 7A, upper panel) , indicating that the majority of TLIMP was localized in the detergent-insoluble membrane fraction. CHO cells transiently overexpressing TLIMP showed retardation of cell growth (Fig. 7A) . It has been reported that TBP-2 suppresses anchorage-dependent and anchorage-independent cell growth (32) , and to test the role of TLIMP in anchorage-independent cell growth, the growth of TLIMPoverproducing HeLa S3 cells was examined in culture in a semisolid medium. The number and size of foci was reduced in TLIMP-and TBP-2-transfected cells (Fig. 7B ). These results demonstrate that both TLIMP and TBP-2 suppress anchorage-dependent and -independent cell growth.
TLIMP suppresses ligand-induced PPAR␥ activation
We next hypothesized that up-regulation of TLIMP by PPAR␥ ligands plays a role in PPAR␥ signaling through feedback regulation. To test this hypothesis, we analyzed the effect of overexpression of TLIMP on PPAR␥ transactivation in NIH3T3 cells, with a reporter assay using a GAL4-fused PPAR␥2 expression vector and a luciferase reporter plasmid containing GAL4 binding sites in the promoter region. As shown in Fig. 8 , troglitazone-induced reporter activation was suppressed by overexpression of TLIMP, suggesting that TLIMP negatively regulates ligand-induced PPAR␥ activation.
PPARs induce the expression of responsive target genes such as FABP4 and LPL through direct binding to the peroxisome proliferator-responsive element in their promoter regions (33, 34) . To investigate the effect of TLIMP on PPAR␥-induced endogenous gene expression, the levels of FABP4, LPL, TLIMP, and TBP-2 were examined in cells overexpressing PPAR␥ and TLIMP. As shown in Fig. 8B , expression of the target genes in cells expressing PPAR␥ increased with treatment with troglitazone. The induction of expression was suppressed by overexpression of TLIMP, suggesting that TLIMP negatively regulates PPAR␥-dependent gene activation.
Discussion
In the present study, we found that there are four familial TBP-2 genes, TBP-2/VDUP1, TLIMP, AF193051, and DRH1 in humans. Members of the human TBP-2 protein family share some common features but also have different features. TBP-2 and AF193051 were predominantly concentrated in the nucleus (20) (Tan, A., S. Oka, M. Mochizuki, H. Masutani, and J. Yodoi, unpublished observation), whereas TLIMP was found in the plasma membrane, lysosomes, and endosomes. The cellular distribution of DRH1 is similar to that of TLIMP; EGFP-tagged DRH1 has been found to be predominantly distributed in small vesicular structures at the periphery of the nucleus in COS7 cells (26) , suggesting the localization in endosomes and/or lysosomes. TBP-2 familial proteins may coordinately regulate common cellular functions in different subcellular compartments. TBP-2 proteins have remote homology to the arrestin family of proteins, which play an important role in the internalization of G protein-coupled receptors and transforming growth factor-␤, thereby quenching their signal transduction (35, 36) . Based on the structural homology, TLIMP may have a similar biological role such as protein trafficking during endocytosis as well as scaffold or adaptor function similar to arrestin (37) . Indeed, overexpression of TLIMP suppressed the uptake of transferrin (data not shown). It could be also postulated that TLIMP itself is associated with endocytosis of VD3 or endogenous ligands of PPAR␥.
Expression levels of TLIMP and TBP-2 were significantly up-regulated by VD3 and PPAR␥ agonists, rather than by RA and PMA, in HL-60 cells (Fig. 5) . These results indicate that the induction of TLIMP and TBP-2 expression in HL-60 cells is specifically associated with differentiation of monocytes and not with granulocytes. In addition, TLIMP and TBP-2 were up-regulated in association with differentiation of adipocytes (Fig. 6) , indicating that these genes play an important role in PPAR␥-mediated adipogenesis or lipid metabolism. The promoter regions of the TLIMP and TBP-2 genes do not have a classical VDR or PPAR response element. The mechanism of the regulations should be further investigated.
We have several pieces of evidence that the expressions of TBP-2 familial genes are differentially regulated. VD3 and PPAR␥ agonists failed to induce the expression of both AF193051 and DRH1 in HL-60 cells (data not shown). In addition, suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, induced expression of TBP-2 expression but not TLIMP in HeLa S3 cells (supplemental Fig. 2 , published as supplemental data on The Endocrine Society's Journals Online web site at http:/ /endo.endojournals.org), although a nuclear factor-Y-binding site is conserved in the TLIMP and TBP-2 promoter regions. It is reported that suberoylanilide hydroxamic acid induces the expression of TBP-2 through activation of nuclear factor-Y (17) .
TLIMP and TBP-2 suppressed both anchorage-dependent and -independent cell proliferation (Fig. 7) . These activities may contribute to the growth-suppressive effects of VD3 and PPAR agonists, which also inhibit anchorage-dependent and -independent cell growth (38, 39) .
The mechanism of TLIMP-induced growth inhibition is currently unclear. Inhibition of the TRX-reducing activity or an effect on the nuclear compartment has been suggested as a mechanism of TBP-2-induced cell growth inhibition (20, 40) . However, it is unlikely that TLIMP suppresses cell growth through inhibition of TRX-reducing activity because it failed to bind to TRX or inhibit its reducing activity (Fig.  3 ). There are many important cell growth-regulating molecules including receptor tyrosine kinases, nonreceptor tyrosine kinases, and (small) G-proteins in the plasma membrane, whose endocytosis leads to a quenching of the signal transduction elicited by the molecules (41) . VD3 modulates signal transduction proximal to the plasma membrane for phospholipase C, protein kinase C, and calcium channels (1). In addition, it is reported that 15-deoxy-⌬-12, 14-prostaglandin J2, a natural ligand for PPAR␥, prevents cell proliferation through inhibition of ErbBs, a receptor tyrosine kinase family (42) . It is possible that TLIMP suppresses cell growth through the modulation of signal transduction in the plasma membrane and/or endosomes. On the other hand, TLIMP suppresses ligand-induced PPAR␥ activation (Fig. 8) , suggesting the negative feedback loop between TLIMP and PPAR␥. In addition to ligand binding, PPAR␥ activity is modulated by MAPK through direct phosphorylation (43) . TLIMP may modulate the activity of PPAR␥ through the regulation of up-stream signaling of these kinases in proximal plasma membrane. The mechanism of the effect of TLIMP in cell proliferation and PPAR␥ activation requires further study.
In conclusion, we have shown that TLIMP, a VD3 or PPAR␥ target protein, regulates cell proliferation and PPAR␥ activation. The cellular localization associated with endocytotic membrane trafficking suggests that TLIMP is a molecule connecting the PPAR␥ signal and endosomal functions, providing a novel mechanism of regulation by VD3 or PPAR␥ signals .
